These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29978322)

  • 1. Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects.
    Choi SK; Kim CW; Kim JT; Seomun Y; Park MS; Kim CO
    Clin Drug Investig; 2018 Sep; 38(9):829-835. PubMed ID: 29978322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial effect of Batroxobin on blood loss reduction in spinal fusion surgery: a prospective, randomized, double-blind, placebo-controlled study.
    Hu HM; Chen L; Frary CE; Chang CC; Hui H; Zhang HP; Huang DG; Liu ZK; Zhao YT; He SM; Zhang XF; He BR; Hao DJ
    Arch Orthop Trauma Surg; 2015 Apr; 135(4):491-7. PubMed ID: 25720848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacodynamics and pharmacokinetics of batroxobin in Beagle dog].
    Zheng ZH; Zhu XX; Gan H; Gu RL; Wu ZN; Meng ZY; Dou GF
    Yao Xue Xue Bao; 2013 Aug; 48(8):1307-11. PubMed ID: 24187841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
    CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of hemocoagulase for improvement of coagulation and reduction of bleeding in fracture-related hip hemiarthroplasty geriatric patients: A prospective, single-blinded, randomized, controlled study.
    Qiu M; Zhang X; Cai H; Xu Z; Lin H
    Injury; 2017 Apr; 48(4):914-919. PubMed ID: 28238301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
    Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
    J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and repeated dose (28 days) toxicity studies in rats and dogs of recombinant batroxobin, a snake venom thrombin-like enzyme expressed from Pichia pastoris.
    Kim OH; Cho KS; Seomun Y; Kim JT; Chung KH
    Toxicon; 2017 Apr; 129():153-163. PubMed ID: 28161122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effective control of a bleeding injury using a medical adhesive containing batroxobin.
    You KE; Koo MA; Lee DH; Kwon BJ; Lee MH; Hyon SH; Seomun Y; Kim JT; Park JC
    Biomed Mater; 2014 Apr; 9(2):025002. PubMed ID: 24487019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris.
    You WK; Choi WS; Koh YS; Shin HC; Jang Y; Chung KH
    FEBS Lett; 2004 Jul; 571(1-3):67-73. PubMed ID: 15280019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro effects of hemocoagulase atrix and its effective components on blood coagulation of patients with bleeding disorders].
    Wang RJ; Wang ZY; Jiang MH; Zhang W; Cao LJ; Sun XH; Zhang J; Bai X; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):376-80. PubMed ID: 22541102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
    Lenfors S; Gustafsson D
    Semin Thromb Hemost; 1996; 22(4):335-42. PubMed ID: 8944418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis.
    Ding J; Zhou D; Hu Y; Elmadhoun O; Pan L; Ya J; Geng T; Wang Z; Ding Y; Ji X; Meng R
    J Thromb Thrombolysis; 2018 Oct; 46(3):371-378. PubMed ID: 30062617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice.
    Adili R; Jackson M; Stanger L; Dai X; Li M; Li BX; Holinstat M
    Clin Appl Thromb Hemost; 2021; 27():10760296211018510. PubMed ID: 34047195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.
    Kim J; Lee SH; Boyce M; Warrington S; Cho KH; Yoon SK; Park HD; Kim A
    Xenobiotica; 2015; 45(8):663-71. PubMed ID: 25673087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant batroxobin expressed highly in Pichia pastoris].
    Li ZF; Yu XL; Huang JL; Fang HQ; Chen HP
    Sheng Wu Gong Cheng Xue Bao; 2007 May; 23(3):483-6. PubMed ID: 17577998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional improvement of hemostatic dressing by addition of recombinant batroxobin.
    Seon GM; Lee MH; Kwon BJ; Kim MS; Koo MA; Kim D; Seomun Y; Kim JT; Park JC
    Acta Biomater; 2017 Jan; 48():175-185. PubMed ID: 27769944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
    Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; Lemm G
    J Thromb Haemost; 2012 May; 10(5):773-80. PubMed ID: 22353395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.